Recursion Pharmaceuticals Inc (NASDAQ:RXRX) traded at $5.11 at close of the session on Friday, June 20 and made an upward move of 5.03% on its previous day’s price.
Looking at the stock we see that its previous close was $6.67 and the beta (5Y monthly) reads 0.833 with the day’s price range being $4.9 – $5.355. In terms of its 52-week price range, RXRX has a high of $12.36 and a low of $3.79. The company’s stock has gained about 10.55% over that past 30 days.
Recursion Pharmaceuticals Inc has a market cap of $2.04 billion and is expected to release its quarterly earnings report on 2025-May-05.
Based on estimates by 3 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Recursion Pharmaceuticals Inc (RXRX) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
The average price target for the stock over the next 12 months is $6, with the estimates having a low of $6 and a high of $6. These price ends are -17.42% and -17.42% off the current price level respectively, although investors could be excited at the prospect of a -17.42% if the RXRX share price touches on the median price of $6.
Coming back to Recursion Pharmaceuticals Inc (NASDAQ:RXRX), we note that the average 3-month trading volume was 1.36, while that of the preceding 10-day period stands at 37.02 million. Current shares outstanding are 399.15 million.
The insiders hold 23.55% of the company’s shares while institutions hold 60.53%. The data shows that short shares as of 2025-05-30, stood at 109.03 million at a short ratio of 5.28. This represents a 2894.00 short interest in shares outstanding on 2025-05-30. Shares short rose in May from the previous month at 93.12 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -46.32% down in year-to-date price movement.
